Microrna-21 blockade of triple negative breast cancer

Ended Project Grant Awarded Last action

Award ID
R41CA235707
Recipient
Awarding agency
Obligated
$299,405

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Place of performance
New Jersey, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment -$185
Amendment Microrna-21 blockade of triple negative breast cancer - triple negative breast cancer (tnbc) is an orphan disease that attacks 46,000 US women every year.… -$185
Original award $299,774

Quick answers

Who received award R41CA235707?

R41CA235707 was awarded to Bound Therapeutics LLC by National Cancer Institute (National Institutes of Health) on June 15, 2019.

How much is award R41CA235707 worth?

$299,405 has been obligated on R41CA235707.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award